Discounted Cash Flow
Alterity Therapeutics Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | — | — | — | — |
| 2017 | — | $-7.5m | $-5.9m | — | $-1.41 |
| 2018 | $201.2k | $-8.3m (-9.6%) | $-6.2m (-6.5%) | -4108.8% | $-1.55 (-9.9%) |
| 2019 | $108.5k (-46.0%) | $-12.3m (-49.3%) | $-14.0m (-123.4%) | -11367.3% (-176.7%) | $-2.00 (-29.0%) |
| 2020 | $17.1k (-84.2%) | $-13.5m (-9.1%) | $-9.4m (32.4%) | -78616.6% (-591.6%) | $-1.50 (25.0%) |
| 2021 | $20.7k (20.8%) | $15.3m (213.8%) | $-17.3m (-83.8%) | 74044.1% (194.2%) | $-0.90 (40.0%) |
| 2022 | $2.5k (-87.9%) | $12.8m (-16.1%) | $-12.3m (28.8%) | 513061.5% (592.9%) | $-0.53 (41.1%) |
| 2023 | $16.4k (556.4%) | $13.8m (7.5%) | $-20.0m (-62.4%) | 84001.7% (-83.6%) | $-0.57 (-7.5%) |
| 2024 | $268.4k (1533.1%) | $-19.1m (-238.2%) | $-12.6m (37.1%) | -7107.3% (-108.5%) | $-0.52 (8.8%) |
| 2025 | $446.3k (66.3%) | $-12.1m (36.7%) | $-11.5m (9.2%) | -2706.7% (61.9%) | $-0.19 (63.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.